You are here

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Beijing Cancer Hospital/Oncology department
Beijing, Beijing, 100142 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- ER(+), HER2(-), postmenopausal adult (ages 18-65 years, inclusive) Chinese women with
proven diagnosis of adenocarcinoma of the breast with evidence locoregionally
recurrent or metastatic disease not amenable to resection or radiation therapy with
curative intent and for whom chemotherapy is not clinically indicated.

a. Postmenopausal women: i. Prior bilateral surgical oophorectomy; or ii. Medically
confirmed post-menopausal status defined as spontaneous cessation of regular menses
for at least 12 consecutive months with no alternative pathological or physiological
cause b. Documentation of histologically or cytologically confirmed diagnosis of: i.
ER(+) breast cancer. c. Documentation of HER2(-) breast cancer. d. Previously
untreated with any systemic anti cancer therapy for their locoregionally recurrent or
metastatic ER+ disease.

- Measurable disease as defined per RECIST v.1.1 or bone-only disease. - Tumor lesions
previously irradiated or subjected to other locoregional therapy will only be deemed
measurable if disease progression at the treated site after completion of therapy is
clearly documented.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- HER2-positive tumor as defined by documentation of erbB-2 gene amplification by FISH
(as defined by a HER2/CEP17 ratio ?2) or chromogenic in situ hybridization (CISH, as
defined by the manufacturer's kit instruction) or documentation of HER2 overexpression
by IHC (defined as IHC3+, or IHC2+ with FISH or CISH confirmation) based on local
laboratory results

- Patients with advanced, symptomatic, visceral spread, that are at risk of
life-threatening complications in the short term (including patients with massive
uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and
over 50% liver involvement).

NCT02499146
Pfizer
Active, not recruiting
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hormone Receptor Positive Advanced Breast Cancer, Metastatic Breast Cancer, Human Epidermal Receptor 2 Negative Advanced Breast Cancer, Castration Resistant Prostate Cancer
NCT03685591
All Genders
18+
Years
Multiple Sites
Advanced Breast Cancer, Metastatic Breast Cancer
NCT03280303
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now